管理层内部使用该等指标进行规划、预测和衡量本集团的整体表现。本集团认为该经调整财务指标为我们及投资者提供有用且有意义的资料，因为其提升投资者对本集团业务持续经营表现及便于比较过去和未来期间的业绩。该等经调整财务指标为非GAAP指标应被视为附加于而不是替代根据GAAP<\/span>原则编制的资料。其他公司可能以其他方法定义该等指标。<\/p> \n

不包括融资活动的调整后的集团净现金流：<\/i>本集团将期内短期投资变动计入期内现金及现金等价物变动，并扣除期内融资活动（所得）\/所用的现金净额以计算出不包括融资活动的调整后的集团净现金流。本集团认为，不包括融资活动的调整后的集团净现金流的呈列就有关在扣除可能存在重大期间差异的融资活动现金流量后的资金资源使用提供有用及有意义的资料。<\/p> \n

固定汇率：<\/i>我们使用上年度的外币汇率转换本年度的业绩进行逐年比较，以消除汇率变化对业绩的影响。因为我们在中国经营着重要的业务，故人民币兑美元的汇率变化可能对我们宣布的业绩拥有重大影响。本集团认为<\/span>，展示以固定汇率计算的业绩提供了有用且有意义的信息，这有助于促进逐年比较并提高我们基本业绩的透明度。<\/p> \n

现金、现金等价物及短期投资的公认会计原则变动与不包括融资活动的调整后的集团净现金流的调节：<\/b><\/p> \n

\n \n \n \n \n \n \n \n
百万美元<\/span><\/p> <\/td> \n

<\/td> \n
2020<\/b>年<\/b><\/span><\/p> <\/td> \n
2019<\/b>年<\/b><\/span><\/p> <\/td> \n <\/tr> \n
年末現金、現金等價物及短期投資<\/span><\/p> <\/td> \n

<\/td> \n
435.2<\/span><\/p> <\/td> \n
217.2<\/span><\/p> <\/td> \n <\/tr> \n
     减: 年初現金、現金等價物及短期投資<\/span><\/p> <\/td> \n

<\/td> \n
(217.2)<\/span><\/p> <\/td> \n
(301.0)<\/span><\/p> <\/td> \n <\/tr> \n
减: 年内融资活动（所得）\/所用的现金流量净额<\/span><\/p> <\/td> \n

<\/td> \n
(296.4)<\/span><\/p> <\/td> \n
1.5<\/span><\/p> <\/td> \n <\/tr> \n
不包括融资活动的调整后的集团净现金流量净额<\/span><\/p> <\/td> \n

<\/td> \n
(78.4)<\/span><\/p> <\/td> \n
(82.3)<\/span><\/p> <\/td> \n <\/tr> \n <\/tbody> \n <\/table> \n<\/div> \n
GAAP<\/span>原则下的收入及和黄医药应占其他业务净溢利变动率相对于固定汇率变动率的调节:<\/b><\/p> \n
\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n
百万美元 (除%外)<\/span><\/p> <\/td> \n
截至<\/b>12<\/b>月<\/b>31<\/b>日<\/b>止年度<\/b><\/span><\/p> <\/td> \n

<\/td> \n
变动金额<\/b><\/span><\/p> <\/td> \n

<\/td> \n
变动率<\/b>%<\/b><\/span><\/p> <\/td> \n <\/tr> \n
2020<\/b>年<\/b><\/span><\/p> <\/td> \n
2019<\/b>年<\/b><\/span><\/p> <\/td> \n

<\/td> \n
实际<\/b><\/span><\/p> <\/td> \n
固定汇率<\/b><\/span><\/p> <\/td> \n
汇率影响<\/b><\/span><\/p> <\/td> \n

<\/td> \n
实际<\/b> <\/b><\/span><\/p> <\/td> \n
固定汇率<\/b><\/span><\/p> <\/td> \n
汇率影响<\/b><\/span><\/p> <\/td> \n <\/tr> \n
综合收入— 其他业务<\/span><\/p> <\/td> \n
197.8<\/b><\/span><\/p> <\/td> \n
178.1<\/b><\/span><\/p> <\/td> \n

<\/td> \n
<\/p>
19.7<\/b><\/span><\/p> <\/td> \n
<\/p>
20.5<\/b><\/span><\/p> <\/td> \n
<\/p>
(0.8)<\/b><\/span><\/p> <\/td> \n

<\/td> \n
<\/p>
11%<\/b><\/span><\/p> <\/td> \n
<\/p>
11%<\/b><\/span><\/p> <\/td> \n
<\/p>
0%<\/b><\/span><\/p> <\/td> \n <\/tr> \n

<\/td> \n
<\/td> \n
<\/td> \n
<\/td> \n
<\/td> \n
<\/td> \n
<\/td> \n
<\/td> \n
<\/td> \n
<\/td> \n
<\/td> \n <\/tr> \n

<\/td> \n
<\/td> \n
<\/td> \n
<\/td> \n
<\/td> \n
<\/td> \n
<\/td> \n
<\/td> \n
<\/td> \n
<\/td> \n
<\/td> \n <\/tr> \n
和黄医药应占综合净溢利<\/span><\/p> <\/td> \n

<\/td> \n
<\/td> \n
<\/td> \n
<\/td> \n
<\/td> \n
<\/td> \n
<\/td> \n
<\/td> \n
<\/td> \n
<\/td> \n <\/tr> \n

<\/td> \n
<\/td> \n
<\/td> \n
<\/td> \n
<\/td> \n
<\/td> \n
<\/td> \n
<\/td> \n
<\/td> \n
<\/td> \n
<\/td> \n <\/tr> \n
不包括白云山和黄中药的一次<\/span><\/p>
性土地收储补偿收益<\/span><\/p> <\/td> \n

<\/td> \n
<\/td> \n
<\/td> \n
<\/td> \n
<\/td> \n
<\/td> \n
<\/td> \n
<\/td> \n
<\/td> \n
<\/td> \n <\/tr> \n
<\/b>其他业务<\/b><\/span><\/p> <\/td> \n
44.0<\/b><\/span><\/p> <\/td> \n
41.5<\/b><\/span><\/p> <\/td> \n

<\/td> \n
2.5<\/b><\/span><\/p> <\/td> \n
3.3<\/b><\/span><\/p> <\/td> \n
(0.8)<\/b><\/span><\/p> <\/td> \n

<\/td> \n
6%<\/b><\/span><\/p> <\/td> \n
8%<\/b><\/span><\/p> <\/td> \n
-2%<\/b><\/span><\/p> <\/td> \n <\/tr> \n
   — 并表附属公司<\/span><\/p> <\/td> \n
2.8<\/span><\/p> <\/td> \n
2.9<\/span><\/p> <\/td> \n

<\/td> \n
(0.1)<\/span><\/p> <\/td> \n
(0.1)<\/span><\/p> <\/td> \n
-<\/span><\/p> <\/td> \n

<\/td> \n
-5%<\/span><\/p> <\/td> \n
-5%<\/span><\/p> <\/td> \n
0%<\/span><\/p> <\/td> \n <\/tr> \n
   — 非并表合资企业<\/span><\/p> <\/td> \n
41.2<\/span><\/p> <\/td> \n
38.6<\/span><\/p> <\/td> \n

<\/td> \n
2.6<\/span><\/p> <\/td> \n
3.4<\/span><\/p> <\/td> \n
(0.8)<\/span><\/p> <\/td> \n

<\/td> \n
7%<\/span><\/p> <\/td> \n
9%<\/span><\/p> <\/td> \n
-2%<\/span><\/p> <\/td> \n <\/tr> \n

<\/td> \n
<\/td> \n
<\/td> \n
<\/td> \n
<\/td> \n
<\/td> \n
<\/td> \n
<\/td> \n
<\/td> \n
<\/td> \n
<\/td> \n <\/tr> \n
土地收储补偿收益<\/b><\/span><\/p> <\/td> \n

<\/td> \n
<\/td> \n
<\/td> \n
<\/td> \n
<\/td> \n
<\/td> \n
<\/td> \n
<\/td> \n
<\/td> \n
<\/td> \n <\/tr> \n
— 白云山和黄中药<\/span><\/p> <\/td> \n
28.8<\/span><\/p> <\/td> \n
-<\/span><\/p> <\/td> \n

<\/td> \n
28.8<\/span><\/p> <\/td> \n
28.8<\/span><\/p> <\/td> \n
-<\/span><\/p> <\/td> \n

<\/td> \n
-<\/span><\/p> <\/td> \n
-<\/span><\/p> <\/td> \n
-<\/span><\/p> <\/td> \n <\/tr> \n <\/tbody> \n <\/table> \n<\/div> \n
<\/p> \n
参考资料和简称<\/b><\/p> \n
\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n
[1]<\/b> 由礼来开具发票的爱优特^{®<\/sup>对第三方的销售额为3,270万美元（2019年：1,760万元）及由和黄医药开具发票的对第三方的销售额为100万美元（2019年：无）<\/i><\/span><\/p> <\/td> \n <\/tr> \n}
[2]<\/b> 礼来 = 礼来公司<\/i><\/span><\/p> <\/td> \n <\/tr> \n
[3]<\/b> MET = 间充质上皮转化因子<\/i><\/span><\/p> <\/td> \n <\/tr> \n
[4]<\/b> MAPK = RAS-RAF-MEK-ERK信号通路<\/i><\/span><\/p> <\/td> \n <\/tr> \n
[5]<\/b> ERK = 细胞外信号调节激酶<\/i><\/span><\/p> <\/td> \n <\/tr> \n
[6]<\/b> VEGFR = 血管内皮生长因子受体<\/i><\/span><\/p> <\/td> \n <\/tr> \n
[7]<\/b> FGFR = 成纤维细胞生长因子受体<\/i><\/span><\/p> <\/td> \n <\/tr> \n
[8]<\/b> CSF-1R = 集落刺激因子-1受体<\/i><\/span><\/p> <\/td> \n <\/tr> \n
[12]<\/b> 君实生物 = 上海君实生物医药科技股份有限公司<\/i><\/span><\/p> <\/td> \n <\/tr> \n
[13]<\/b> PD-1 = 程序性死亡受体1<\/i><\/span><\/p> <\/td> \n <\/tr> \n
[14]<\/b> 百济神州 = 百济<\/span>神州有限公司<\/i><\/span><\/p> <\/td> \n <\/tr> \n
[15]<\/b> IDMC = 独立数据监察委员会<\/i><\/span><\/p> <\/td> \n <\/tr> \n
[16]<\/b> 信达生物 = 信达生物制药（苏州）有限公司<\/i><\/span><\/p> <\/td> \n <\/tr> \n
[19]<\/b> EGFR = 表皮生长因子受体<\/i><\/span><\/p> <\/td> \n <\/tr> \n
[20]<\/b> PI3Kδ = 磷脂酰肌醇3-激酶亚型δ<\/i><\/span><\/p> <\/td> \n <\/tr> \n
[21]<\/b> Syk = 脾酪氨酸激酶<\/i><\/span><\/p> <\/td> \n <\/tr> \n
[22]<\/b> FGFR2 = 成纤维细胞生长因子受体2<\/i><\/span><\/p> <\/td> \n <\/tr> \n
[23]<\/b> IDH1\/2 = 异柠檬酸脱氢酶1\/2<\/i><\/span><\/p> <\/td> \n <\/tr> \n
[24]<\/b> 白云山和黄中药 = 广州白云山和记黄埔中药有限公司<\/i><\/span><\/p> <\/td> \n <\/tr> \n
[25]<\/b> GAAP = 美国公认会计原则<\/i><\/span><\/p> <\/td> \n <\/tr> \n
[26]<\/b> 本年度报告中提及的按照固定汇率报告的财务指标均是基于非GAAP财务指标。请参阅下文“非GAAP财务指标的使用和调节” ，以分别了解与这些财务指标的解释，以及这些财务指标与最具可比性的GAAP指标的对账。<\/i><\/span><\/p> <\/td> \n <\/tr> \n
[27]<\/b> 其他项目 = 包括其他收入、所得税费用、权益性被投资企业盈利中的权益（扣除税款）和归属于非控制性权益的净收入<\/i><\/span><\/p> <\/td> \n <\/tr> \n <\/tbody> \n <\/table> \n<\/div> \n
<\/p> \n
\n<\/div>"]; $("#dvExtra").html(content_array[0]);})();